Patents by Inventor Michael McCall

Michael McCall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5705923
    Abstract: A method and apparatus for varying an electrically variable current limiting reactor (VICLR) ( 16) are provided in cooperation with an electrostatic precipitator automatic voltage control system. The inductance of VICLR (16) is varied by altering the DC current in control winding (66) of VICLR (16). A power source (10) connects serially to an inverse parallel SCR1 and SCR2, to VICLR (16), and to a TR set comprising a transformer (18) and rectifier (20) which supply power to precipitator (22). System electrical characteristics on both sides of the TR set are monitored. Computer (40) uses these monitored values to continuously calculate form factor and fractional conduction values. Step-down transformer (60) is connected to solid state relay (62) which is in turn connected to full wave bridge rectifier (64). Rectifier (64) is connected to control winding (66) of VICLR (16). Solid state relay (62) is also connected to computer (40).
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: January 6, 1998
    Assignee: BHA Group, Inc.
    Inventors: David F. Johnston, Michael McCall Mahler, Timothy Gerald Lawrence
  • Patent number: 4863713
    Abstract: A method and system for localizing a diagnostic or therapeutic agent to an internal target site. The system includes (1) an epitopic compound, (2) a binding protein which is effective to bind specifically with the compound and capable of localizing selectively at the target tissue, when administered parenterally, and (3) a clearing agent which can bind to and cross-link the binding protein, to form a protein aggregate which is readily cleared from the subject's bloodstream. In practicing the method of the invention, the binding protein is administered to the subject parenterally, and allowed to localize at the target site, typically within 1-4 days. This is followed by a chase with the clearing agent to remove circulating, but not target-localized binding protein. When the epitopic compound is administered, binding of the compound to the localized binding protein, and rapid clearance of unbound compound by the kidneys, results in selective localization of the compound at the target site.
    Type: Grant
    Filed: June 23, 1986
    Date of Patent: September 5, 1989
    Assignee: The Board of Trustees of Leland Stanford Jr. Univ.
    Inventors: David A. Goodwin, Claude Meares, Michael McCall